Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-powered digital innovations in pharmaceuticals research & development: Current landscape and case examples.

Journal of biopharmaceutical statistics·2026
Same author

Decentralized Clinical Trials in the Era of Real-World Evidence: A Critical Assessment of Recent Experiences.

Clinical and translational science·2025
Same author

rdborrow: an R package for causal inference incorporating external controls in randomized controlled trials with longitudinal outcomes.

Journal of biopharmaceutical statistics·2025
Same author

Multivariate time series clustering analysis of the Global Dietary Database to uncover patterns in dietary trends (1990-2018).

Public health nutrition·2025
Same author

Decentralized Clinical Trials in the Era of Real-World Evidence: A Statistical Perspective.

Clinical and translational science·2025
Same author

A causal inference framework for leveraging external controls in hybrid trials.

Biometrics·2024

Related Experiment Video

Updated: May 23, 2026

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes.

Inyoung Kim1, Herbert Pang, Hongyu Zhao

  • 1Department of Statistics, Virginia Polytechnic Institute and State University, Blacksburg, VA, U.S.A. inyoungk@vt.edu

Statistics in Medicine
|March 23, 2012
PubMed
Summary

This study introduces a novel Bayesian approach for analyzing gene pathways in relation to clinical outcomes. It offers more accurate results than traditional methods, especially with limited data, improving pathway identification for diseases like type II diabetes.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Experiment Videos

Last Updated: May 23, 2026

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information
05:01

A Pathway Association Study Tool for GWAS Analyses of Metabolic Pathway Information

Published on: July 1, 2020

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Area of Science:

  • Genomics and Bioinformatics
  • Statistical Genetics
  • Computational Biology

Background:

  • Traditional gene analysis methods often overlook subtle, pathway-level changes by focusing on individual genes.
  • Limited research exists on analyzing gene pathways in regression models for continuous or binary clinical outcomes.
  • Understanding gene pathway effects is crucial for complex diseases and personalized medicine.

Purpose of the Study:

  • To propose and evaluate a Bayesian approach for identifying gene pathways associated with continuous and binary clinical outcomes.
  • To compare the proposed Bayesian method with a likelihood-based approach in terms of parameter estimation and pathway effect inference.
  • To assess the performance of different kernel functions (Gaussian, polynomial, neural network) within the Bayesian framework.

Main Methods:

  • Developed a Bayesian hierarchical model to analyze gene expression data within biological pathways.
  • Incorporated prior biological knowledge into the model formulation.
  • Compared the Bayesian approach with a likelihood-based method using simulations and a type II diabetes dataset.

Main Results:

  • The Bayesian approach allows direct estimation of all parameters and pathway effects, unlike the likelihood-based method.
  • Bayesian inference utilizes posterior samples without reliance on asymptotic theory.
  • Simulations showed the Bayesian approach provides more accurate coverage probability, particularly with small sample sizes relative to the number of genes.

Conclusions:

  • The proposed Bayesian method is effective for identifying gene pathways related to clinical outcomes.
  • This approach offers advantages in accuracy and flexibility, especially in scenarios with limited sample sizes.
  • The methodology is applicable to various biological and statistical settings involving numerous correlated predictors.